HEDROS Biotechnology

Hedros Biotechnology is a San Diego-based biotechnology company specializing in the development of oral small molecule inhibitors targeting the IL-17 pathway. The company was established to address the need for oral alternatives to injectable biologic therapies for chronic inflammatory conditions, particularly in dermatology. Its lead programs focus on blocking IL-17 signaling to treat diseases such as psoriasis. In 2021, Hedros Biotechnology was acquired by LEO Pharma, a leader in medical dermatology, to enhance its portfolio of oral treatments for skin diseases. The acquisition allowed LEO Pharma to integrate Hedros's innovative small molecule research into its global R&D pipeline.